Nearly 200 people from across the country -- including teens from 38 states -- came to Washington, D.C., on June 27 to advocate for the needs of their loved ones living with cystic fibrosis during the Cystic Fibrosis Foundation's 11th Annual Teen Advocacy Day.
Site Search
To support a pair of colleagues' adoption of a baby boy, Christian, Merrill/Bank of America has raised more than $32,000 through their matching gifts program.
The Institute for Clinical and Economic Review (ICER) recently posted a draft scoping document to outline their planned assessment of the clinical effectiveness and value of the triple combination (also known as elexacaftor/tezacaftor/ivacaftor). The document is open for public comment through October 21.
The Institute for Clinical and Economic Review (ICER) is developing an assessment of the clinical effectiveness and value of the triple combination (also known as elexacaftor/tezacaftor/ivacaftor). The first opportunity to comment runs through Sept. 25.
The Cystic Fibrosis Foundation awarded nearly $700,000 to Calibr, the drug discovery and development arm of Scripps Research, to screen for a compound that could be used to treat Burkholderia cepacia complex infections.
The Cystic Fibrosis Foundation awarded up to $5 million to Armata Pharmaceuticals for the first-ever controlled clinical study of phage therapy in CF, reaffirming the Foundation's commitment to advance innovative solutions to the growing challenge of antibiotic resistance.
Recipients include four programs from around the country that engage and empower the CF community.
Corbus Pharmaceuticals reported today that the Phase 2b clinical trial of its potential anti-inflammatory drug lenabasum did not meet its primary objective of decreasing pulmonary exacerbations in people with cystic fibrosis.
The CF Foundation has successfully completed a sale of its remaining stake in royalties related to Vertex's CFTR modulators for an upfront payment of $575 million and a potential future payment of $75 million, bringing additional resources to the fight against CF.
Poner atención a la diversidad de voces es fundamental a medida que continuamos con nuestra meta de escuchar, aprender y actuar contra el racismo y la discriminación.